I'm LongbridgeAI. Here is the key information I extracted- The broker expects 4Q revenue growth to slow due to regulatory scrutiny and a high base from last year's influenza outbreak, prompting a slight reduction in the full-year revenue growth forecast to 15 %.…
BofA Securities published a research report stating that JD HEALTH (06618.HK) -7.260 (-17.613%) Short selling $90.55M; Ratio 21.577% experienced operational volatility in 3Q, but its structural growth remains intact. Its 3Q revenue rose 17% YoY, beating expectations, with revenue growth improving from 15% in 2Q. Structural growth remains intact. The broker reiterated its "Buy" rating and maintained its TP at HKD57.
However, considering the impact of regulatory scrutiny on misleading promotions by major brands in the nutrition and healthcare supplements industry, as well as the high comparison base for the pharmaceutical segment due to influenza in 4Q last year, BofA Securities expects JD HEALTH's revenue growth to slow in 4Q. It lowered its full-year revenue growth forecast from 16% to 15%, while maintaining forecasts for adjusted operating profit and net profit growth of 31% YoY and 6% YoY respectively. The broker still believes JD HEALTH's earnings are resilient and can benefit from economies of scale, supply chain efficiency, pharmaceutical margins and operational efficiency, with margins expected to continue expanding.
The broker also slightly lowered its 2026 EPS forecast from RMB2.17 to RMB2.16, while slightly raising its 2027 EPS forecast from RMB2.51 to RMB2.52.(gc/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-17 16:25.)
